The final, formatted version of the article will be published soon.
REVIEW article
Front. Oncol.
Sec. Gynecological Oncology
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1477610
This article is part of the Research Topic The role of non-coding RNAs in gynecological cancers: new perspectives in cancer therapy and prognosis View all 4 articles
The role of extracellular vesicles in the pathogenesis of gynecological cancer
Provisionally accepted- 1 National Institute of Biomedical Genomics (NIBMG), Calcutta, India
- 2 GLA University, Mathura, Uttar Pradesh, India
- 3 The University of Texas Health Science Center at Tyler, Tyler, Texas, United States
- 4 Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- 5 Institute of Management Studies, Ghaziabad, Ghaziabad, India
Gynecological cancer, the most common form of cancers in women worldwide, initiates in the reproductive organs of females. More often, the common treatment measures, i.e. surgery, radiation, and medical oncology are found to be unsuccessful in the treatment of gynecological tumors. Emerging evidence indicates that extracellular vesicles (EVs) play a significant role in the pathogenesis of gynecological cancers by distinct mechanisms. The present review highlights how EVs contribute to the progression of different types of gynecological cancers such as cervical cancer, endometrial cancer, ovarian cancer, vaginal cancer, uterine sarcoma, gestational trophoblastic disease (GTD), and vulvar cancer. The primary focus is to understand how EVs' cargo alters the phenotypic response of the recipient cells, thereby contributing to the progression of the disease, thus can be considered as a prognostic and diagnostic biomarker. A brief discussion on the role of EVs in the diagnosis and prognosis of different gynecological cancer types is also highlighted. Targeting the biogenesis of the EVs, their inside cargo, and EVs uptake by the recipient cells could be a potential therapeutic approach in the treatment of gynecological cancer beside conventional therapeutic means.
Keywords: gynecological cancer, extracellular vesicles, biomarkers, Therapeutic potential, Cancer Progression
Received: 08 Aug 2024; Accepted: 09 Sep 2024.
Copyright: © 2024 Chatterjee, Gupta, Mukherjee, Parashar, Kumar, Maitra and DAS. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Madhura Chatterjee, National Institute of Biomedical Genomics (NIBMG), Calcutta, India
Umesh Kumar, Institute of Management Studies, Ghaziabad, Ghaziabad, 201 009, India
Arindam Maitra, National Institute of Biomedical Genomics (NIBMG), Calcutta, India
KAUSHIK DAS, National Institute of Biomedical Genomics (NIBMG), Calcutta, India
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.